Pharmacogenomics of cytarabine in childhood leukemia-Reference-Cited by-同舟云学术

Pharmacogenomics of cytarabine in childhood leukemia

Published:2011-12 Issue:12 Volume:12 Page:1629-1632
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Lamba Jatinder K¹

Affiliation:

1. Department of Experimental & Clinical Pharmacology, College of Pharmacy, PUMA-Institute of Personalized Medicine, Institute of Human Genetics, 14-281 Moos Tower, Delaware Street SE, MN, USA.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.11.148

Reference22 articles.

1. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.

2. Correlation of cytotoxicity with incorporation of ara-C into DNA.

3. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new technique for the analysis of metabolic pathways of cytidine analogues and cytidine deaminase activities in cells;Scientific Reports;2023-11-22

2. Evaluation of the impact of single-nucleotide polymorphisms on treatment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol;Systematic Reviews;2019-05-03

3. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients;Pharmacogenomics;2018-09-01

4. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma;Pediatric Blood & Cancer;2016-08-31

5. Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia;Pediatric Blood & Cancer;2015-01-03